Tags

Type your tag names separated by a space and hit enter

[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ugeskr Laeger. 2003 Jan 27; 165(5):456-9.UL

Abstract

INTRODUCTION

Left ventricular hypertrophy is a strong independent predictor of risk of cardiovascular morbidity and death. The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy.

MATERIAL AND METHODS

The LIFE-study included 9193 patients with essential hypertension and ECG-verified left ventricular hypertrophy, age range 55-80 years, systolic blood pressure in sitting position 160-200 mmHg and/or diastolic blood pressure 95-115 mmHg. Patients were randomized to double-blind treatment with losartan versus atenolol. They were followed for at least four years and until 1040 patients had a primary cardiovascular event (cardiovascular death, myocardial infarction or stroke).

RESULTS

Blood pressure fell by 30.2/16.6 and 29.1/16.8 mmHg in the losartan and the atenolol group, respectively. The primary composite endpoint occurred in 508 losartan and 588 atenolol patients (relative risk 0.87, p = 0.021). A total of 232 and 309, respectively, had fatal or non-fatal stroke (relative risk 0.75, p = 0.001). There was no difference in myocardial infarction. New-onset diabetes was 25% less frequent on losartan. Side effects were less on losartan compared to atenolol.

DISCUSSION

Losartan prevents to a higher degree cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated.

Authors+Show Affiliations

Medicinsk Afdeling M, Amtssygehuset i Glostrup.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
English Abstract
Journal Article
Randomized Controlled Trial

Language

dan

PubMed ID

12599843

Citation

Ibsen, Hans, et al. "[The Effect of Losartan Versus Atenolol On Cardiovascular Morbidity and Mortality in Patients With Hypertension and ECG-verified Left Ventricular Hypertrophy in the LIFE-study]." Ugeskrift for Laeger, vol. 165, no. 5, 2003, pp. 456-9.
Ibsen H, Pedersen OL, Dahlöf B, et al. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. Ugeskr Laeger. 2003;165(5):456-9.
Ibsen, H., Pedersen, O. L., Dahlöf, B., Kjeldsen, S. E., & Lindholm, L. H. (2003). [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. Ugeskrift for Laeger, 165(5), 456-9.
Ibsen H, et al. [The Effect of Losartan Versus Atenolol On Cardiovascular Morbidity and Mortality in Patients With Hypertension and ECG-verified Left Ventricular Hypertrophy in the LIFE-study]. Ugeskr Laeger. 2003 Jan 27;165(5):456-9. PubMed PMID: 12599843.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. AU - Ibsen,Hans, AU - Pedersen,Ole Lederballe, AU - Dahlöf,Björn, AU - Kjeldsen,Sverre E, AU - Lindholm,Lars H, PY - 2003/2/26/pubmed PY - 2003/4/11/medline PY - 2003/2/26/entrez SP - 456 EP - 9 JF - Ugeskrift for laeger JO - Ugeskr Laeger VL - 165 IS - 5 N2 - INTRODUCTION: Left ventricular hypertrophy is a strong independent predictor of risk of cardiovascular morbidity and death. The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy. MATERIAL AND METHODS: The LIFE-study included 9193 patients with essential hypertension and ECG-verified left ventricular hypertrophy, age range 55-80 years, systolic blood pressure in sitting position 160-200 mmHg and/or diastolic blood pressure 95-115 mmHg. Patients were randomized to double-blind treatment with losartan versus atenolol. They were followed for at least four years and until 1040 patients had a primary cardiovascular event (cardiovascular death, myocardial infarction or stroke). RESULTS: Blood pressure fell by 30.2/16.6 and 29.1/16.8 mmHg in the losartan and the atenolol group, respectively. The primary composite endpoint occurred in 508 losartan and 588 atenolol patients (relative risk 0.87, p = 0.021). A total of 232 and 309, respectively, had fatal or non-fatal stroke (relative risk 0.75, p = 0.001). There was no difference in myocardial infarction. New-onset diabetes was 25% less frequent on losartan. Side effects were less on losartan compared to atenolol. DISCUSSION: Losartan prevents to a higher degree cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated. SN - 0041-5782 UR - https://www.unboundmedicine.com/medline/citation/12599843/[The_effect_of_losartan_versus_atenolol_on_cardiovascular_morbidity_and_mortality_in_patients_with_hypertension_and_ECG_verified_left_ventricular_hypertrophy_in_the_LIFE_study]_ L2 - https://medlineplus.gov/highbloodpressure.html DB - PRIME DP - Unbound Medicine ER -